To evaluate the role of the deleted in colorectal carcinoma (DCC) gene in leukemogenesis, we examined loss of heterozygosity (LOH) in the DCC gene in 64 primary human leukemias using Southern blot analysis and examined the expression of the DCC gene using reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. Allelic loss in the DCC gene was observed in two patients (6%, 2 of 35 inf...

Chronic myelogenous leukemia (CML) blast crisis is an ominous clinical event that is challenging to treat. This can develop at extramedullary sites rarely and is defined as the infiltration of blasts outside the bone marrow irrespective of proliferation of blasts within the bone marrow. We aim to report an unusual clinical presentation characterized by Horner's syndrome, ipsilateral arm weaknes...

Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective transplant and nontransplant treatment approaches to CML have been developed that increase the options available to newly diagnosed patients, and that can cure or prolong survival in this formerly incurable disease. Newly diagnosed patient...

The effectiveness of donor-lymphocyte infusion (DLI) for treatment of relapsed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation is a clear demonstration of the graft-versus-leukemia (GVL) effect. T cells are critical mediators of GVL, but the antigenic targets of this response are unknown. To determine whether patients who respond to DLI also develop B-cell immuni...

Thy-1 (CDw90) is a phosphatidylinositol-anchored cell surface molecule which, when coexpressed with CD34 in normal human bone marrow, identifies a population of immature cells that includes putative hematopoietic stem cells. To date, the characterization of Thy-1 expression has been confined largely to normal tissues and cell lines. In this study, we evaluated the frequency and intensity of Thy...

Multidrug resistance protein-1 (MDR1) has been proven to be associated with the development of chemoresistance to imatinib (Glivec, STI571) which displays high efficacy in treatment of BCR-ABL-positive chronic myelogenous leukemia (CML). However, the possible mechanisms of MDR1 modulation in the process of the resistance development remain to be defined. Herein, galectin-1 was identified as a c...

The paper is devoted to the study of a mathematical model of drug therapy for Chronic Myelogenous Leukemia (CML). The disease dynamics are given by a couple of delay differential equations that describe the interaction between a stem-like population of CML cells and a more mature, differentiated one, without self-renewal properties. A molecular targeted therapy, such as Imatinib, is considered....

press. 32. Bumm T, Mueller C, Leiblein S. Restoration of polyclonal hematopoiesis in most CML patients in complete cytogenetic remission to imatinib but rapid emergence of clonal cytogenetic abnormalities in Ph-negative cells in a subset of patients. Blood 2002;100: 613a[abstract]. 33. Druker BJ, Sawyers CL, Capdeville R. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 20...

Chronic myelogenous leukemia (CML) is associated with the Philadelphia (Ph) chromosome. which results from a reciprocal translocation between chromosomes 9 and 22. This activates the abi oncogene by moving it from chromosome 9 and combining it with sequence located on chromosome 22. The new fusion gene. with chromosome 22 sequence at its 5’ end and chromosome 9-abl sequence at its 3’ end. gener...

Chronic myeloid leukemia (CML), a hematologic malignancy characterized by unregulated growth of myelogenous leukocytes, typically presents with symptoms of fatigue, anorexia, and splenomegaly. Laboratory studies often reveal a significant leukocytosis with neutrophilia. A moderate thrombocytosis may be present, but is not usually problematic. The following case discusses a patient who presented...